<DOC>
	<DOC>NCT01136174</DOC>
	<brief_summary>To investigate safety of BIBF 1120 in Japanese patients with idiopathic pulmonary fibrosis (IPF), with and without pirfenidone background treatment. To assess pharmacokinetics of BIBF 1120 in Japanese patients, with and without pirfenidone background treatment. To assess pharmacokinetics of pirfenidone in Japanese patients, alone and in combination with BIBF 1120 treatment.</brief_summary>
	<brief_title>Safety and PK Study of BIBF 1120 in Japanese Patients With IPF</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Inclusion criteria: 1. Diagnosis of idiopathic pulmonary fibrosis (IPF) according to American Thoracic Society (ATS) /European Respiratory Society (ERS) guideline 2. Forced vital capacity (FVC) 5090% 3. Diffusing capacity for carbon monoxide (DLCO) 3079% 4. For patients on pirfenidone, have been on a steady dose for at least 3 months Exclusion criteria: 1. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) &gt; 1.5 x upper limit of normal range (ULN) at screening. 2. Bilirubin &gt; 1.5 x ULN at screening. 3. Relevant airways obstruction (i.e. prebronchodilator FEV1/FVC &lt;0.7) at screening. 4. Continuous oxygen supplementation. 5. Active infection at screening or randomisation. 6. Being treated with any of the following concomitant medications. Oral corticosteroid medication at unstable dose ketoconazole or atazanavir 7. Patients who are expected to go on to lung transplantation, have rapidly deteriorating disease, or have a life expectancy less than 3 months from screening</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>